CClinicalTrials.gg
CompletedNCT01746303Updated May 27, 2016

Omega-3 and Blueberry Supplementation in Age-Related Cognitive Decline

An interventional study of Omega-3 fatty acid and Blueberry powder in Age-related Memory Disorders and Mood Disorders, sponsored by University of Cincinnati. Completed at 1 site in United States. Open to participants aged 62 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-05-27.

Sponsored by University of Cincinnati · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
94
Allocation
Randomized
Ages
62 Years to 80 Years
Sex
All
01

Study summary

The aim of this study is to determine the efficacy of 6 months' dietary supplementation with omega-3 fatty acids and whole freeze dried blueberry powder in improving cognition in older adults. The effects of each of these interventions alone will also be assessed in order to determine whether the combined treatment confers synergistic or additive benefit relative to the effect of each therapy.

Read the detailed description

After meeting inclusion criteria, one hundred-forty men and women, aged 62 to 80 years old, will be enrolled and randomly assigned to one of four groups: 1) omega-3 fatty acid and blueberry powder supplement, 2) omega-3 fatty acid and placebo powder, 3) placebo oil and blueberry powder supplement, or 4) placebo oil and placebo powder. They will participate in a 24-week intervention with major assessments including neuropsychological and functional evaluation at pre-treatment baseline and during the final week of the intervention. In addition, an interim evaluation of neurocognitive function will be conducted at 12 weeks. Subjects will be asked to maintain diet diaries for three periods during the study. Mood will be assessed as a potential covariate of the neurobehavioral outcome measures and data on red blood cell fatty acid content, metabolic parameters, inflammation, and anthropometric factors will be gathered to assess compliance and explore individual differences in response to the intervention and to evaluate potential mechanisms of action.

02

Conditions studied

  • Age-related Memory Disorders
  • Mood Disorders

Keywords

  • Working memory
  • Long-term memory
  • Neurocognition
  • Dietary supplementation
  • dementia
03

In context

Memory Disorders

260 studies on the registry are indexed under Memory Disorders; 60 are open to participants now.

This study's enrollment of 94 is above the median of 73 across 207 interventional studies indexed under Memory Disorders.

Browse Memory Disorders studies →

Lead sponsor

University of Cincinnati is the lead sponsor of 314 studies on the registry; 43 are open to participants now.

Of its 22 completed or terminated interventional studies of FDA-regulated products, 15 (68%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
62 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • men and women aged 62 to 80 years and older
  • age-associated decline operationalized as Clinical Dementia Rating = 0, Auditory Verbal Learning Test cumulative acquisition score between 1.0 standard deviation below and 1.0 standard deviation above the age-corrected mean or Montreal Cognitive Assessment score greater than 25, and Geriatric Depression Scale score less than 16
  • ability to comprehend and comply with the research protocol
  • provision of written informed consent.

Exclusion criteria

Exclusion Criteria:

  • established dementia or neurological disorder including but not limited to probable Alzheimer's Disease, Parkinson's Disease, Frontotemporal dementia, multi-infarct dementia, and leukoencephalopathy
  • current or past severe psychiatric disorder such as psychosis or major mood disorder requiring hospitalization and/or causing a change in level of occupational or social functioning
  • current or past alcohol or drug abuse disorder causing physiological dependence or change in functional capability (nicotine dependence is permitted)
  • diagnosis of diabetes or other metabolic disorder or kidney or liver disease
  • use of medication that might affect outcome measures or interact with omega 3 fatty acid supplements such as benzodiazepines, aspirin, and serotonin reuptake inhibitors
  • hematological coagulation disorder
  • allergy to shellfish or seafood; 8) current supplementation with fish oil or consumption of fish more than once per week.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
94 participants (actual)

Study arms

  • Experimental
    Omega 3 and Blueberry powder

    This group will receive omega-3 fatty acid and blueberry powder supplement for 24 weeks (6 months)

    Dietary Supplement: Omega-3 fatty acid · Dietary Supplement: Blueberry powder

  • Experimental
    Omega-3 and placebo powder

    This group will receive omega-3 fatty acid and placebo powder for 24 weeks (6 months)

    Dietary Supplement: Omega-3 fatty acid · Other: Placebo powder

  • Experimental
    Placebo oil and blueberry powder

    This group will receive placebo oil and blueberry powder for 24 weeks (6 months).

    Dietary Supplement: Blueberry powder · Other: Placebo oil

  • Placebo comparator
    Placebo oil and placebo powder

    This group will receive placebo oil and placebo powder for 24 weeks (6 months)

    Other: Placebo oil · Other: Placebo powder

Interventions

  • Dietary supplementOmega-3 fatty acid

    A fixed dose of 2.4 g/day (EPA: 1.6 g, DHA: 0.8 g; 4 capsules/d).

    Also known as: OmegaRx capsules

  • Dietary supplementBlueberry powder

    Whole, freeze-dried blueberry powder made of 50%:50% mixture of Tifblue and Rubel blueberries.

  • OtherPlacebo oil

    Corn oil capsules that are identical in size, shape, and color to omega-3 capsules.

  • OtherPlacebo powder

    Placebo powder matched for color, taste, and sugar content as closely as possible and milled similarly to the blueberry powder.

06

What researchers measure

Primary outcomes

  1. Working Memory and Executive Ability

    The following tests will be administered to measure working memory function: * Porteus Maze Test * Verbal Primary Memory with Interference Test * Letter Number Sequencing Task * Controlled Oral Word Production Task

    Time frame: 6 months

Secondary outcomes

  1. Mood Assessment

    The following scale will be used to assess mood: * Geriatric Depression Scale * Geriatric Anxiety Inventory

    Time frame: 6 months

  2. Daily Functioning Assessment

    The following scale will be used to measure daily functioning: - Older Americans Resources and Services Functional Assessment Questionnaire

    Time frame: 6 months

  3. Long-term memory function

    The following assessments will be conducted to measure Long-term memory function: * California Verbal Learning Test, Second Edition * Visual Nonverbal Recognition Memory Test * Verbal Paired Associate Learning Task * Spatial Paired Associate Learning Task

    Time frame: 6 months

Other outcomes

  1. Ancillary Measures

    The following measures will be collected: * Red blood cell fatty acid composition * Inflammatory and metabolic parameters * Waist Circumference, Hip Circumference, Height, Body Weight, Blood pressure, Heart rate * Urinary anthocyanin studies * Diet Diaries

    Time frame: 6 months

07

Study locations

1 site
  • University of Cincinnati
    Cincinnati, Ohio 45219, United States
08

References and documents

Publications

  • McNamara RK, Kalt W, Shidler MD, McDonald J, Summer SS, Stein AL, Stover AN, Krikorian R. Cognitive response to fish oil, blueberry, and combined supplementation in older adults with subjective cognitive impairment. Neurobiol Aging. 2018 Apr;64:147-156. doi: 10.1016/j.neurobiolaging.2017.12.003. Epub 2017 Dec 12. PubMed 29458842 ↗
  • Boespflug EL, McNamara RK, Eliassen JC, Schidler MD, Krikorian R. Fish Oil Supplementation Increases Event-Related Posterior Cingulate Activation in Older Adults with Subjective Memory Impairment. J Nutr Health Aging. 2016 Feb;20(2):161-9. doi: 10.1007/s12603-015-0609-6. PubMed 26812512 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 27, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01746303
Lead sponsor
University of Cincinnati
Responsible party
Robert Krikorian (Professor, University of Cincinnati) — Principal investigator
First posted
Dec 10, 2012
Start date
Jan 2010
Primary completion
Jan 2016
Completion
Jan 2016
Last update
May 27, 2016

Study contacts

Robert Krikorian, PhD
principal investigator · University of Cincinnati
Robert McNamara, PhD
principal investigator · University of Cincinnati

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion